Full metadata record
DC FieldValueLanguage
dc.contributor.authorWang, Y. -J.en_US
dc.contributor.authorLin, E. -T.en_US
dc.contributor.authorChen, Y. -T.en_US
dc.contributor.authorChiu, P. -C.en_US
dc.contributor.authorLin, B. -S.en_US
dc.contributor.authorChiang, H. -M.en_US
dc.contributor.authorHuang, Y. -H.en_US
dc.contributor.authorWang, K. -Y.en_US
dc.contributor.authorLin, H. -Y.en_US
dc.contributor.authorChang, T. -M.en_US
dc.contributor.authorChang, C. -C.en_US
dc.date.accessioned2020-07-01T05:21:22Z-
dc.date.available2020-07-01T05:21:22Z-
dc.date.issued2020-03-01en_US
dc.identifier.issn0926-9959en_US
dc.identifier.urihttp://dx.doi.org/10.1111/jdv.15934en_US
dc.identifier.urihttp://hdl.handle.net/11536/154459-
dc.description.abstractBackgroundRecent evidence suggests melasma to be a photoaging disorder. Triple combination creams (TCC: fluocinolone acetonide 0.01%, hydroquinone 4% and tretinoin 0.05%) remain the gold standard treatment. Picosecond alexandrite laser treatment using a diffractive lens array (DLA) has been identified to be effective for improving photoaging conditions. ObjectiveWe aimed to compare the efficacy and tolerance of the picosecond alexandrite laser with those of DLA and TCC in female Asian patients with melasma. MethodsTwenty-nine patients were randomly assigned to group A1 (3 laser sessions at 4-week intervals), A2 (5 laser sessions at 4-week intervals) or B (TCC daily for at least 8 weeks and then tapered until the final evaluation). The Melasma Area, Severity Index (MASI) score and VISIA were assessed at baseline, week 12 and week 20. By week 20, the follow-up periods for groups A1 and A2 were 3 months and 1 month, respectively. ResultsNine, 11 and 6 participants in groups A1, A2 and B completed the study, respectively. MASI scores were significantly improved in all 3 groups at weeks 12 and 20. In groups A1, A2 and B, the improvement rates at week 20 were 53%, 38% and 50%, respectively. VISIA((R)) analysis additionally revealed a significant improvement in spots, porphyria, pores and brown spots after 3 laser sessions (P < 0.05). Group A2 showed greater improvements than group A1 in terms of spots, wrinkles and pores; however, only red areas were significantly different (P < 0.001). All side-effects in the 3 groups were transient and gradually subsided after 1-3 months. ConclusionPicosecond alexandrite laser treatment using DLA showed comparable efficacy with TCC for the treatment of melasma. Improvements in texture, spots, wrinkles and pores were observed in the laser groups. Patients with melasma lesions that exhibit telangiectasia may benefit from additional laser treatment sessions.en_US
dc.language.isoen_USen_US
dc.titleProspective randomized controlled trial comparing treatment efficacy and tolerance of picosecond alexandrite laser with a diffractive lens array and triple combination cream in female asian patients with melasmaen_US
dc.typeArticleen_US
dc.identifier.doi10.1111/jdv.15934en_US
dc.identifier.journalJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGYen_US
dc.citation.volume34en_US
dc.citation.issue3en_US
dc.citation.spage624en_US
dc.citation.epage632en_US
dc.contributor.department影像與生醫光電研究所zh_TW
dc.contributor.departmentInstitute of Imaging and Biomedical Photonicsen_US
dc.identifier.wosnumberWOS:000529420700052en_US
dc.citation.woscount1en_US
Appears in Collections:Articles